Budget Cuts from FY11 Continue in FY12

The budget deal that provides funding for the federal government through the end of this fiscal year resulted in budget cuts to several health research agencies. The National Institutes of Health was cut by about 1% or $320 million, the National Science Foundation was cut by 1% or $60 million, the Agency for Healthcare Research and Quality was cut by 6% or $25 million, and the Centers for Disease Control and Prevention received the most significant cut of about 12% or $748 million. The Food and Drug Administration received a 4.5% increase of $107 million.

The NIH has stated that all institutes and centers will be subject to a 1% decrease in support for research grants from the FY10 levels. National Cancer Institute grants, however, will be reduced by 3% from the FY10 award levels. Several NIH programs will be exempt from cuts, including Career Awards, SBIR/STTR and the National Research Service Award. During a recent hearing on FY12 appropriations for NIH, Director Francis Collins, MD, PhD, estimated that grant funding rates for the current fiscal year and FY12 may be 17%, the lowest rate in NIH history.

The CDC also released its plan for the remainder of FY11. A variety of

-- Continued on page 4

Research!America, Pfizer, University of Maryland Host Science Journalism Forum

Research!America, together with Pfizer, Inc and the University of Maryland, held a Research Partners Forum, “Let Me Be Clear: Science Journalism in the Age of the Genome and Twitter,” an interactive dialogue about how journalists and scientists can work together in the evolving environments of both fields.

The event marked the release of a new Research!America poll on Marylanders’ views of science and coverage of science.

Susan Dentzer, editor-in-chief of Health Affairs, moderated two panels of experts.

-- Continued on page 7

Research!America, NEOMED Host Ohio Research Partners Forum

Research!America and Northeast Ohio Medical University (NEOMED) hosted a Research Partners Forum, “Building Ohio’s Economy and Health Through Medical Research.” Attended by 400 people, the forum focused on the importance of medical research to Ohio’s economy.

Results of a new Ohio poll by IBOPE Zogby, commissioned by Research!America, were released at the event. The findings showed Ohioans see the importance of investment in medical and health research to job creation and the economy in their state: 80% believe spending money on scientific research is important to Ohio’s economy in terms of jobs and incomes.

-- Continued on page 5

Most Americans Think R&D is Important to State Economies

<table>
<thead>
<tr>
<th>Importance</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Very Important</td>
<td>41%</td>
</tr>
<tr>
<td>Somewhat Important</td>
<td>50%</td>
</tr>
<tr>
<td>Not Too Important</td>
<td>8%</td>
</tr>
<tr>
<td>Not At All Important</td>
<td>1%</td>
</tr>
</tbody>
</table>

SOURCE: YOUR CONGRESS–YOUR HEALTH SURVEY, MARCH 2011, CHARLTON RESEARCH COMPANY FOR RESEARCH!AMERICA
The Buck Institute for Research on Aging

The Buck Institute for Research on Aging sits amid the hills north of San Francisco in Novato, CA. The Institute traces its origins to the estate of Beryl Hamilton Buck, who died in 1975; one of the stipulations of her estate was to “extend help towards the problems of the aged.” After several years of development, the institute opened in August 1999.

Aging is the largest risk factor for chronic disease, cancers and neurodegenerative diseases among them. Brian Kennedy, PhD, The Buck Institute’s CEO and president, sees his institution as one of several that is searching for the biological mechanisms at the root of aging and age-related disease.

“I’ll be honest, we haven’t completely solved the mystery,” Kennedy, who was named to his current position in July 2010, says with a laugh. “But, we’ve developed—here and at other institutes as well—a lot of interventions that we can go in and actually slow the aging process in animals.”

The Buck Institute remains the country’s only independent research facility dedicated to understanding the link between aging and chronic disease. Kennedy said the institute is also focusing more on translational research—a push to bring basic discoveries from the laboratory to the clinic.

The Buck Institute is also in the midst of constructing the complex’s second research facility; in all, four are scheduled to be built. The newest will focus on stem cell research and regenerative medicine, Kennedy said.

“It’s become a very promising approach to look at how we can use stem cells to replenish defective tissue,” he said. “And aging is about defective tissue.”

He added that The Buck Institute is a Research!America member for several reasons. Most importantly is the need to effectively communicate the message that research saves lives.

“There are a lot of great institutions doing research that’s meant to help [the public],” Kennedy said. “... The main reason is to help people, and Research!America helps communicate that message for us and for everyone.”

For more information, visit www.buckinstitute.org.
**University of Montana Op-eds on Research Funding**
Research!America worked with Richard Bridges, PhD, at the University of Montana’s College of Health Professions and Biomedical Sciences, on op-eds published in the Missoulian, The Billings Gazette and the Helena Independent Record. The op-eds address the importance of investing in research for Montana’s economy, competitiveness and for the health of all Montanans.

**John Edward Porter Quoted in the News**
A Q&A with Research!America’s chair, former Illinois Congressman John Edward Porter, was published in Nature Medicine and picked up in Stanford Medicine’s SCOPE blog. In it, Porter recounted his work as House LHHS subcommittee chair that led to the doubling of the National Institutes of Health budget. Porter also talked about the strong connection between research funding and job creation in articles in Bloomberg News and The Nation. In BioPharm International, he described the need to spur biomedical innovation to maintain the U.S. global competitiveness. “America’s position as the world leader in biomedical R&D is under siege today, facing its biggest threat in 65 years,” he said. “Is America going to put progress on hold?”

**ACS-CAN and LIVESTRONG Oppose Research Funding Cuts**
John Seffrin, PhD, CEO of The American Cancer Society-Cancer Action Network and a Research!America board member, and Lance Armstrong, chairman of the LIVESTRONG Foundation, held a news conference at the National Press Club in Washington, DC, to urge Congress to oppose cuts to cancer research and prevention programs. Their message received press coverage in Forbes magazine, Newsday and other media outlets.

**Mainstream, Trade Publications Interview Mary Woolley**
Research!America CEO Mary Woolley commented on the final FY11 budget for NIH and the National Science Foundation in The Washington Post’s Federal Eye blog and BNA’s Medical Research Law & Policy Report. In these articles and in The Washington Times, she emphasized that investing in science and research is necessary for the U.S. to maintain its global economic competitiveness. In The Scientist, she praised the new study by Battelle and the Life Technologies Foundation on the economic impact of the Human Genome Project. She said: “I hope that our nation’s elected officials take heed of the value demonstrated by the Battelle report issued today to reassess any plans to cut research in the FY12 budget.”

**Garfield Economic Impact Award in the News**
Frank Lichtenberg, PhD, professor of business at Columbia Business School and the winner of Research!America’s 2010 Garfield Economic Impact Award, published an op-ed in Nature Medicine about the cost-effectiveness of new cancer drugs, arguing that they are worth their high cost because of the number of life-years saved and the value of those life-years. New York Times columnist and three-time Garfield Economic Impact Award moderator David Leonhardt received the 2011 Pulitzer Prize for Commentary.
Budget Cuts Continue in FY12
Continued from page 1

CDC programs will be subject to cuts, and the full details of the operating plan are available on the budget section of the CDC website. Other agencies are currently drafting their spending plans for the remainder of FY11.

For FY12, the House Committee on Appropriations announced budget sub-allocations for the 12 subcommittees. The Subcommittee on Labor, HHS, and Education (LHHS), which provides funding for NIH, CDC and AHRQ, was allocated $139 billion for FY12, an $18 billion decrease from FY11 enacted levels. The proposed level of $139 billion is lower than the enacted level from FY05. The Subcommittee on Commerce, Justice, and Science (CJS) was provided $50 billion for FY12, a $5 billion decrease. Subcommittee markups for CJS and LHHS are scheduled for July 7 and July 26, respectively.

Freshman Briefing
On May 11, Research!America co-sponsored a meeting held by Rep. Dan Benishek, MD (R-MI). The meeting provided an opportunity for several freshmen Members of Congress to meet Francis Collins.

Rep. Austin Scott (R-GA), Rep. Mike Kelly (R-PA), Rep. Larry Bucshon, MD (R-IN) and Rep. John Carney (D-DE) also attended the meeting.

Benishek opened the meeting by introducing Collins and thanking those in attendance. After Collins provided a brief overview of NIH, the Members were given an opportunity to ask questions about health and biomedical research. The Q&A discussion touched on a variety of issues and challenges facing health and health research. The importance of prevention was discussed as a cost-effective means for improving health while lowering overall health spending. Collins mentioned the importance of personalized medicine and new technology to foster healthy behaviors in patients. But he also informed members about the challenges facing the NIH. Collins estimates that grant award rates at NIH could dip as low as 17% due to funding constraints, which would be the lowest in history.

Overall, the freshmen members in attendance seemed supportive of research to improve health and interested in health research issues. They all received personal invitations to take a tour of the NIH.

Campaign for Public Health
The CPH Foundation recently led a bipartisan group of 27 congressional staff from the House of Representatives on a tour of the Centers for Disease Control and Prevention headquarters in Atlanta. The group walked through the agency’s emergency response center; met with the agency’s director, Thomas Frieden, MD, MPH; and had in-depth discussions with several other senior CDC staff.

More than 50 congressional offices responded to CPH’s letter of invitation.

<table>
<thead>
<tr>
<th>Agency</th>
<th>C.R. for FY 11</th>
<th>President’s 2012 Budget</th>
<th>2012 R!A Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Institutes of Health</td>
<td>$30.2 billion</td>
<td>$32 billion</td>
<td>$35 billion</td>
</tr>
<tr>
<td>Centers for Disease Control and Prevention*</td>
<td>$5.7 billion</td>
<td>$6.3 billion</td>
<td>$7.7 billion</td>
</tr>
<tr>
<td>National Science Foundation</td>
<td>$6.8 billion</td>
<td>$7.76 billion</td>
<td>$7.76 billion</td>
</tr>
<tr>
<td>Agency for Healthcare</td>
<td>$372 million</td>
<td>$397 million</td>
<td>$405 million</td>
</tr>
</tbody>
</table>

* Reflects the CDC core program budget.
Bernanke: Value of Government’s Role in R&D

Ben Bernanke, chairman of the Federal Reserve, said that government support of R&D can help boost economic growth and is more effective if “thought of as a long-run investment” and when stable support is provided.

Bernanke made the remarks at a conference on jobs and growth at Georgetown University in May.

“To the extent that countries gain from leadership in technologically vibrant industries or from local spillovers arising from inventive activity,” Bernanke said, “… Governments that choose to provide support for R&D are likely to get better results if that support is stable, avoiding a pattern of feast or famine.”

Your Congress–Your Health Poll Released

Research!America’s recent Your Congress–Your Health poll gauges Americans’ attitudes on research funding and other issues related to health, science and innovation. As we emerge from the recession, 78% of Americans think federal funding for health research is important for job creation and the economy and 91% think R&D is important to their state’s economy. Additionally, 76% think global health R&D is important to the U.S. economy.

The poll findings were cited in Nature Medicine’s Spoonful of Medicine blog, Stanford Medicine’s SCOPE blog, United Press International and Asian News International, among other news outlets.

For more, visit www.yourcongressyourhealth.org.

Reports Link Research, Economic Impact

Two new reports show just how much medical research has contributed to the U.S. economy.

United for Medical Research, of which Research!America is a member, found that nearly 488,000 jobs were supported by the National Institutes of Health. The figures, calculated by a method developed by the Department of Commerce, also found that 16 states had 10,000 or more jobs funded by NIH extramural research.

A report from Battelle and Life Technologies Foundation, both Research!America members, found that taxpayers’ investment in the Human Genome Project has repaid many times the original cost. The nearly $4 billion U.S. investment in the Human Genome Project resulted in an economic impact of $796 billion and $244 billion in total personal income—all thanks to the economic activity that has sprung up from the initial investment.

Research Partners Forum

Continued from page 1

Susan Dentzer, editor-in-chief of Health Affairs, moderated a panel discussion on the subject. Panelists included Carolyn Clancy, MD, director, Agency for Healthcare Research and Quality; Barbara Kunz, president, Health and Life Sciences Global Business, Battelle; Debra Lappin, JD, senior vice president, B&D Consulting and president, Council for American Medical Innovation; Rep. Tim Ryan, U.S. Congressman; and Lawrence Tabak, DDS, PhD, principal deputy director, National Institutes of Health.

The panel discussed the ways research creates new jobs and allows people to live longer, healthier lives.

The panel preceded comments on the importance of research to education and its economic impact on Ohio colleges and universities from eight members of the Inter-University Council of Ohio Presidents.

Battelle and NEOMED are Research!America members. Dentzer is a Research!America board member.
The Alliance for Aging Research released a new *Silver Book*, an almanac of research and data, on thrombosis.

Research!America’s Mary Woolley has become a National Advisor for the Council for the Advancement of Science Writing.

The Alzheimer’s Association was recognized as the best large nonprofit organization to work for in a national survey published in April by *The Nonprofit Times*.

The American Association for the Advancement of Science has released *Working With Congress*, which helps scientists learn how to talk to their elected representatives.

Research!America has released a fact sheet on the National Institutes of Health—this month’s newsletter insert—highlighting the contributions to global health R&D by the NIH as part of our U.S. federal agency and department fact sheet series. The NIH is the largest source of global health research in the world. This support of global health R&D stimulates job growth here at home, promotes a stable global economy and ensures a safer, healthier world. Visit www.researchamerica.org/global_health to download the fact sheet and find more resources about the impact of global health R&D.

The United States Patent and Trademark Office held a gathering at Stanford University to address how it can improve its customer service, including its ability to reduce the backlog of patent applications. Since a significant percentage of the USPTO’s work involves medicines and medical devices, such improvements could mean accelerated access to new or improved health products.

Entrepreneurs, patent attorneys, venture capitalists and experts in start-ups attended the conference, along with principals from the USPTO, including Director David Kappos.

The USPTO heard several requests, including that patent examiners work more closely with inventors, that U.S. and global patent regulations become more closely aligned, and that the PTO find a way to increase the pace of patent review.

Research!America has released a fact sheet on NIH Global Health R&D.

The American Association for Cancer Research presented its first Award for Distinguished Service and Global Impact in Cancer and Biomedical Research to Research!America board chair John Edward Porter. Mary J.C. Hendrix, PhD, president and scientific director of Children’s Memorial Research Center and a Research!America board member, received an honorary Doctor of Science degree from Lake Forest College in Lake Forest, IL. Martha Hill, PhD, RN, dean of the Johns Hopkins University School of Nursing and also a Research!America board member, received an honorary Doctor of Public Health degree from Flinders University in Adelaide, Australia.

AACR, Children’s Memorial Research Center and the Johns Hopkins University School of Nursing are Research!America members.

Some spending cuts & strategic investment needed for economy:

- Spending cuts are not a priority now as our economy recovers from the recession: 6%
- Some spending cuts are necessary but the U.S. must invest strategically to improve the health of the economy: 53%
- Across-the-board spending cuts are necessary to reduce the federal budget deficit and improve the health of the U.S. economy: 35%
- Don’t know: 6%

*Source: Your Congress—Your Health Survey, March 2011, Charlton Research Company for Research!America*
The research advocate

RD ADVOCACY

GLOBAL HEALTH

Research!America recognized HIV Vaccine Awareness Day on May 18 and leaders in HIV vaccine R&D.

The successful introduction of an effective HIV vaccine could have a significant impact. According to the International AIDS Vaccine Initiative (IAVI), an AIDS vaccine that is at least 50% effective given to 30% of the population would avert 5.6 million new infections in low- and middle-income countries in just 15 years.

With numbers like that in mind, NIH and groups like IAVI have taken novel approaches to speed HIV vaccine R&D. NIH recently announced a shift towards adaptive trial designs to accelerate trials based on evidence as it is acquired. IAVI’s model, a public-private partnership, works across typical business and geographic boundaries to develop and bring health products quickly and safely to market.

The recent progress has brought hope, but the need for continued R&D remains paramount. “No single HIV prevention strategy will control and ultimately end the HIV/AIDS pandemic,” said Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases. “That is why it is important to continue supporting promising research [for HIV prevention, testing, and treatment].”

Research!America extends special thanks to our principal partners

Program Partners
- American Diabetes Association
- Council for American Medical Innovation
- The Foundation Fighting Blindness
- March of Dimes
- Vradenburg Foundation

Research Partners Forum
- Battelle

Your Congress–Your Health
- Association of Independent Research Institutes
- Assurant Health

National Health Research Forum
- Pharmaceutical Research and Manufacturers of America (PhRMA)

2011 Advocacy Awards
- American Heart Association (Sponsor)
- B&D Consulting, LLC (Friend sponsor)

Biotechnology Industry Organization
- Council for American Medical Innovation (Friend sponsor)
- Genentech, Inc. (Patron sponsor)
- The Johns Hopkins University (Principal Partner)
- Johnson & Johnson (Program Partner)
- MWW Group
- Morgan Stanley Smith Barney
- NewYork-Presbyterian Hospital (Sponsor)
- Partners Healthcare System/Massachusetts General Hospital/Brigham & Women’s Hospital (Program Partner)
- Pharmaceutical Research and Manufacturers of America (PhRMA)
- Dr. Raymond R. and Mrs. Beverly Sackler (Benefactor)
- UnitedHealth Group (Presenting Partner)
- University of California, San Francisco (Friend sponsor)
- Van Andel Research Institute (Friend sponsor)

Visit www.researchamerica.org/partnership_opportunities for ways to support Research!America.

AMERICA SPEAKS

How important would you say it is that the U.S. work to improve health globally through research and development?

Majority Say U.S. Global Health R&D is Important

Very Important 30%
Somewhat Important 48%
Not Too Important 17%
Not At All Important 5%

SOURCE: YOUR CONGRESS–YOUR HEALTH SURVEY, MARCH 2011, CHARLTON RESEARCH COMPANY FOR RESEARCH!AMERICA

G L O B A L  H E A L T H

R & D
A D V O C A Y
Coming UP


June 6-7, 2011—NLM/FNLM Clinical Trials: New Challenges & Opportunities, Natcher Conference Center, National Institutes of Health, Bethesda, MD. www.fnlm.org


Advocacy & Action

Where Do Your Policy Makers Stand?

Research!America and our partners have launched Your Congress—Your Health. Every Member of Congress has been invited to respond to a questionnaire about medical research, the deficit and support for federal agencies that conduct research to improve health (NIH, FDA, CDC, NSF and AHRQ). Please contact your representative and senators TODAY to urge them to respond to the questionnaire at www.yourcongressyourhealth.org.

Cuts to research funding have already occurred at NIH, NSF, CDC and AHRQ. That is why it is more important than ever for Americans to know where lawmakers stand on these critical issues.

Visit US ON THE WEB

www.researchamerica.org

Connect with Research!America Online

Follow us on Twitter: www.twitter.com/researchamerica

Become a fan on Facebook: www.researchamerica.org/facebook

Watch our YouTube channel: www.youtube.com/researchamerica

Visit our blog: www.researchamerica.org/blog
The National Institutes of Health is the largest source of global health research in the world. NIH-funded research takes place at universities and institutions in all 50 states and through public-private partnerships around the world in 90+ countries, fueling our economy and leading to health breakthroughs that save lives.

**The NIH Impact**

- awards 50,000 competitive grants and contracts to 330,000 researchers annually [Source: NIH]
- every 1 research grant awarded results in 7 new jobs [Source: NIH]
- more than 80% of NIH funding supports research at partner institutions [Source: NIH]
- every $1 million that NIH invests generates $2 million in new state business activity [Source: Research!America]
- awarded $7,538,694 in funding support to global health product development partnerships in 2009 [Source: GFinder 2010, Policy Cures]

Failing to fund the NIH adequately would lead to the loss of a generation of scientists dedicated to curing disease, combating rising health care costs, and making Americans and people everywhere healthier.

“We believe NIH should be funded at a level commensurate with the tremendous potential and importance of basic research. Government-supported basic research is one key to how we collectively progress in discovering novel compounds for addressing patients’ unmet medical needs.”

JOHN J. CASTELLANI  President and Chief Executive Officer, Pharmaceutical Research and Manufacturers of America

**Smart Collaborations in Global Health**

**Product Development Partnerships**

The International Partnership for Microbicides (IPM) is a global health product development partnership based in Silver Spring, Maryland, with a clinical office in South Africa. With support from NIH, IPM is working with community partners, non-governmental organizations, pharmaceutical companies, clinical research centers and others to develop antiretroviral-based microbicides in the form of gels and long acting rings designed to safely offer women protection against HIV/AIDS — the number one killer of women ages 15-44 around the world. Building on evidence-based practices, IPM, NIH, and their partners are working together to improve our health, contribute to our economy, and offer an affordable new product to save lives.
The National Institutes of Health support global health R&D that stimulates job growth at home, promotes a stable global economy and ensures a safer, healthier world. Cross-collaboration between the 27 different institutes at the NIH and other partners allows for leveraged expertise and unique insight as the NIH works to improve health worldwide.


- The Joint NIH-FDA Leadership Council ensures early communication and an improved regulatory review process, speeding up the time it takes medicines to get from the lab to patients all over the world. NIH and FDA Announce Collaborative Initiative to Fast-track Innovations to the Public, 2010.

- The National Institute of Child Health and Human Development (NICHD) and The National Institute of Allergy and Infectious Diseases (NIAID) recently worked together to research and develop a vaccine for the dengue virus, currently being tested in clinical trials, that could potentially protect people in 100+ countries, including the United States, that report dengue annually. http://www.nih.gov/catalyst/2010/10.12.01/catalyst_v18i6.pdf

- NIH research in Australian aboriginals led to the discovery of the Hepatitis B virus and vaccine. Today, all American children are immunized against Hepatitis B with a vaccine which also protects against liver cancer. NIH Medline Plus – Worldwide Discoveries Help People Everywhere, 2008.

- All 27 NIH institutes and centers support the Trans-NIH AIDS research program. The world’s largest program of its kind, it has led to the development of treatments and advances in prevention that protect families both at home and abroad. Department of Health and Human Services, National Institutes of Health, Office of AIDS Research Trans-NIH AIDS Research Budget, Congressional Justification for FY 2012.

- Overseen by seven NIH institutes, the Rare Diseases Clinical Research Network conducts groundbreaking research on 95 global rare diseases and has enrolled more than 5,000 subjects in 37 clinical studies since 2003. http://www.nih.gov/newshealth/vic2003and-05.htm

- Over 40% of all research and development in this country is supported by the NIH. charltonresearch.com

- Less than one penny of every U.S. health dollar goes toward global health R&D.